File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Controllable dual-release of dexamethasone and bovine serum albumin from PLGA/β-tricalcium phosphate composite scaffolds

TitleControllable dual-release of dexamethasone and bovine serum albumin from PLGA/β-tricalcium phosphate composite scaffolds
Authors
Keywordsbovine serum albumin
dexamethasone
dual-release
microsphere
scaffold
Issue Date2011
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.interscience.wiley.com/jpages/0021-9304:1/
Citation
Journal Of Biomedical Materials Research - Part B Applied Biomaterials, 2011, v. 96 B n. 1, p. 139-151 How to Cite?
AbstractLocalized dual-drug delivery from biodegradable scaffolds is an important strategy in tissue engineering. In this study, porous poly(L-lactide-co- glycolide) (PLGA)/β-tricalcium phosphate scaffolds containing both dexamethasone (Dex) and bovine serum albumin (BSA) were prepared by incorporating Dex-loaded and BSA-loaded microspheres into the scaffolds. PLGA microspheres containing Dex or BSA were prepared by spray-drying and double emulsion/solvent evaporation, respectively. In vitro release studies indicated that microspheres prepared from PLGA in 3:1 molar ratio of L-lactide/glycolide and 89.5 kDa relative molecular mass showed prolonged release profiles compared with those prepared from PLGA in 1:1 L-lactide/glycolide molar ratio and 30.5 kDa relative molecular mass. Additionally, introduction of poly(ethylene glycol) in the PLGA chain could improve the encapsulation efficiency and reduce the release rate. Based on the above results, controllable dual-release of Dex and BSA with relatively higher or lower release rate was achieved by incorporating Dex-loaded and BSA-loaded microspheres with different release profiles into the PLGA/β-tricalcium phosphate scaffolds. © 2010 Wiley Periodicals, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/139386
ISSN
2015 Impact Factor: 2.881
2015 SCImago Journal Rankings: 0.784
ISI Accession Number ID
Funding AgencyGrant Number
Natural Science Foundation of China30828008
Funding Information:

Contract grant sponsor: Natural Science Foundation of China; contract grant number: 30828008

References

 

DC FieldValueLanguage
dc.contributor.authorYang, Yen_HK
dc.contributor.authorTang, Gen_HK
dc.contributor.authorZhang, Hen_HK
dc.contributor.authorZhao, Yen_HK
dc.contributor.authorYuan, Xen_HK
dc.contributor.authorWang, Men_HK
dc.contributor.authorYuan, Xen_HK
dc.date.accessioned2011-09-23T05:49:03Z-
dc.date.available2011-09-23T05:49:03Z-
dc.date.issued2011en_HK
dc.identifier.citationJournal Of Biomedical Materials Research - Part B Applied Biomaterials, 2011, v. 96 B n. 1, p. 139-151en_HK
dc.identifier.issn1552-4973en_HK
dc.identifier.urihttp://hdl.handle.net/10722/139386-
dc.description.abstractLocalized dual-drug delivery from biodegradable scaffolds is an important strategy in tissue engineering. In this study, porous poly(L-lactide-co- glycolide) (PLGA)/β-tricalcium phosphate scaffolds containing both dexamethasone (Dex) and bovine serum albumin (BSA) were prepared by incorporating Dex-loaded and BSA-loaded microspheres into the scaffolds. PLGA microspheres containing Dex or BSA were prepared by spray-drying and double emulsion/solvent evaporation, respectively. In vitro release studies indicated that microspheres prepared from PLGA in 3:1 molar ratio of L-lactide/glycolide and 89.5 kDa relative molecular mass showed prolonged release profiles compared with those prepared from PLGA in 1:1 L-lactide/glycolide molar ratio and 30.5 kDa relative molecular mass. Additionally, introduction of poly(ethylene glycol) in the PLGA chain could improve the encapsulation efficiency and reduce the release rate. Based on the above results, controllable dual-release of Dex and BSA with relatively higher or lower release rate was achieved by incorporating Dex-loaded and BSA-loaded microspheres with different release profiles into the PLGA/β-tricalcium phosphate scaffolds. © 2010 Wiley Periodicals, Inc.en_HK
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.interscience.wiley.com/jpages/0021-9304:1/en_HK
dc.relation.ispartofJournal of Biomedical Materials Research - Part B Applied Biomaterialsen_HK
dc.rightsJournal of Biomedical Materials Research Part B: Applied Biomaterials. Copyright © John Wiley & Sons, Inc.-
dc.subjectbovine serum albuminen_HK
dc.subjectdexamethasoneen_HK
dc.subjectdual-releaseen_HK
dc.subjectmicrosphereen_HK
dc.subjectscaffolden_HK
dc.subject.meshAntimicrobial Cationic Peptides - chemistry-
dc.subject.meshDexamethasone - chemistry-
dc.subject.meshDrug Implants - chemistry-
dc.subject.meshSerum Albumin, Bovine - chemistry-
dc.subject.meshTissue Scaffolds - chemistry-
dc.titleControllable dual-release of dexamethasone and bovine serum albumin from PLGA/β-tricalcium phosphate composite scaffoldsen_HK
dc.typeArticleen_HK
dc.identifier.emailWang, M:memwang@hku.hken_HK
dc.identifier.authorityWang, M=rp00185en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/jbm.b.31752en_HK
dc.identifier.pmid21086430-
dc.identifier.scopuseid_2-s2.0-78650009799en_HK
dc.identifier.hkuros193977en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-78650009799&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume96 Ben_HK
dc.identifier.issue1en_HK
dc.identifier.spage139en_HK
dc.identifier.epage151en_HK
dc.identifier.isiWOS:000285225500017-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridYang, Y=36669427500en_HK
dc.identifier.scopusauthoridTang, G=23494188700en_HK
dc.identifier.scopusauthoridZhang, H=13305519300en_HK
dc.identifier.scopusauthoridZhao, Y=23494436100en_HK
dc.identifier.scopusauthoridYuan, X=7402202601en_HK
dc.identifier.scopusauthoridWang, M=15749714100en_HK
dc.identifier.scopusauthoridYuan, X=7402202655en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats